832 related articles for article (PubMed ID: 22851558)
1. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802.
Shaw EG; Wang M; Coons SW; Brachman DG; Buckner JC; Stelzer KJ; Barger GR; Brown PD; Gilbert MR; Mehta MP
J Clin Oncol; 2012 Sep; 30(25):3065-70. PubMed ID: 22851558
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma.
Bell EH; Zhang P; Shaw EG; Buckner JC; Barger GR; Bullard DE; Mehta MP; Gilbert MR; Brown PD; Stelzer KJ; McElroy JP; Fleming JL; Timmers CD; Becker AP; Salavaggione AL; Liu Z; Aldape K; Brachman DG; Gertler SZ; Murtha AD; Schultz CJ; Johnson D; Laack NN; Hunter GK; Crocker IR; Won M; Chakravarti A
J Clin Oncol; 2020 Oct; 38(29):3407-3417. PubMed ID: 32706640
[TBL] [Abstract][Full Text] [Related]
3. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.
Brada M; Stenning S; Gabe R; Thompson LC; Levy D; Rampling R; Erridge S; Saran F; Gattamaneni R; Hopkins K; Beall S; Collins VP; Lee SM
J Clin Oncol; 2010 Oct; 28(30):4601-8. PubMed ID: 20855843
[TBL] [Abstract][Full Text] [Related]
5. One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre.
Keogh RJ; Aslam R; Hennessy MA; Coyne Z; Hennessy BT; Breathnach OS; Grogan L; Morris PG
BMC Cancer; 2021 Feb; 21(1):140. PubMed ID: 33557783
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.
van den Bent MJ; Brandes AA; Taphoorn MJ; Kros JM; Kouwenhoven MC; Delattre JY; Bernsen HJ; Frenay M; Tijssen CC; Grisold W; Sipos L; Enting RH; French PJ; Dinjens WN; Vecht CJ; Allgeier A; Lacombe D; Gorlia T; Hoang-Xuan K
J Clin Oncol; 2013 Jan; 31(3):344-50. PubMed ID: 23071237
[TBL] [Abstract][Full Text] [Related]
7. Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.
Erdem-Eraslan L; Gravendeel LA; de Rooi J; Eilers PH; Idbaih A; Spliet WG; den Dunnen WF; Teepen JL; Wesseling P; Sillevis Smitt PA; Kros JM; Gorlia T; van den Bent MJ; French PJ
J Clin Oncol; 2013 Jan; 31(3):328-36. PubMed ID: 23269986
[TBL] [Abstract][Full Text] [Related]
8. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial.
Medical Research Council Brain Tumor Working Party
J Clin Oncol; 2001 Jan; 19(2):509-18. PubMed ID: 11208845
[TBL] [Abstract][Full Text] [Related]
10. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
Cairncross G; Wang M; Shaw E; Jenkins R; Brachman D; Buckner J; Fink K; Souhami L; Laperriere N; Curran W; Mehta M
J Clin Oncol; 2013 Jan; 31(3):337-43. PubMed ID: 23071247
[TBL] [Abstract][Full Text] [Related]
11. Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02.
Prabhu RS; Won M; Shaw EG; Hu C; Brachman DG; Buckner JC; Stelzer KJ; Barger GR; Brown PD; Gilbert MR; Mehta MP
J Clin Oncol; 2014 Feb; 32(6):535-41. PubMed ID: 24419119
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma.
Qian Y; Maruyama S; Kim H; Pollom EL; Kumar KA; Chin AL; Harris JP; Chang DT; Pitt A; Bendavid E; Owens DK; Durkee BY; Soltys SG
Neuro Oncol; 2017 Nov; 19(12):1651-1660. PubMed ID: 28666368
[TBL] [Abstract][Full Text] [Related]
13. To treat or not to treat? A retrospective multicenter assessment of survival in patients with IDH-mutant low-grade glioma based on adjuvant treatment.
Paľa A; Coburger J; Scherer M; Ahmeti H; Roder C; Gessler F; Jungk C; Scheuerle A; Senft C; Tatagiba M; Synowitz M; Wirtz CR; Schmitz B; Unterberg AW
J Neurosurg; 2019 Jul; ():1-8. PubMed ID: 31323633
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.
van den Bent MJ; Carpentier AF; Brandes AA; Sanson M; Taphoorn MJ; Bernsen HJ; Frenay M; Tijssen CC; Grisold W; Sipos L; Haaxma-Reiche H; Kros JM; van Kouwenhoven MC; Vecht CJ; Allgeier A; Lacombe D; Gorlia T
J Clin Oncol; 2006 Jun; 24(18):2715-22. PubMed ID: 16782911
[TBL] [Abstract][Full Text] [Related]
15. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.
Cairncross JG; Wang M; Jenkins RB; Shaw EG; Giannini C; Brachman DG; Buckner JC; Fink KL; Souhami L; Laperriere NJ; Huse JT; Mehta MP; Curran WJ
J Clin Oncol; 2014 Mar; 32(8):783-90. PubMed ID: 24516018
[TBL] [Abstract][Full Text] [Related]
16. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
McDuff SGR; Dietrich J; Atkins KM; Oh KS; Loeffler JS; Shih HA
Cancer Med; 2020 Jan; 9(1):3-11. PubMed ID: 31701682
[TBL] [Abstract][Full Text] [Related]
17. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
; Cairncross G; Berkey B; Shaw E; Jenkins R; Scheithauer B; Brachman D; Buckner J; Fink K; Souhami L; Laperierre N; Mehta M; Curran W
J Clin Oncol; 2006 Jun; 24(18):2707-14. PubMed ID: 16782910
[TBL] [Abstract][Full Text] [Related]
18. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.
Prados MD; Seiferheld W; Sandler HM; Buckner JC; Phillips T; Schultz C; Urtasun R; Davis R; Gutin P; Cascino TL; Greenberg HS; Curran WJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1147-52. PubMed ID: 15001257
[TBL] [Abstract][Full Text] [Related]
19. Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma.
van den Bent MJ
Neuro Oncol; 2014 Dec; 16(12):1570-4. PubMed ID: 25355680
[TBL] [Abstract][Full Text] [Related]
20. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.
Buckner JC; Shaw EG; Pugh SL; Chakravarti A; Gilbert MR; Barger GR; Coons S; Ricci P; Bullard D; Brown PD; Stelzer K; Brachman D; Suh JH; Schultz CJ; Bahary JP; Fisher BJ; Kim H; Murtha AD; Bell EH; Won M; Mehta MP; Curran WJ
N Engl J Med; 2016 Apr; 374(14):1344-55. PubMed ID: 27050206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
